Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats

Synapse ◽  
2010 ◽  
Vol 64 (7) ◽  
pp. 533-541 ◽  
Author(s):  
Boris Ferger ◽  
Kerstin Buck ◽  
Makoto Shimasaki ◽  
Eliza Koros ◽  
Patrizia Voehringer ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Animal Models ◽  
Early Morning ◽  
In Vivo Microdialysis ◽  
Continuous Dopaminergic Stimulation ◽  
Pharmacodynamic Study ◽  
Dopaminergic Stimulation

scholarly journals Effectiveness and mechanisms of adipose-derived stem cell therapy in animal models of Parkinson’s disease: a systematic review and meta-analysis

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Keya Li ◽  
Xinyue Li ◽  
Guiying Shi ◽  
Xuepei Lei ◽  
Yiying Huang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Animal Models ◽  
Therapeutic Option ◽  
Meta Analysis ◽  
Future Application ◽  
Neuroprotective Effects ◽  
Standard Mean Difference ◽  
Study Characteristics

AbstractAnimal models provide an opportunity to assess the optimal treatment way and the underlying mechanisms of direct clinical application of adipose-derived stem cells (ADSCs). Previous studies have evaluated the effects of primitive and induced ADSCs in animal models of Parkinson’s disease (PD). Here, eight databases were systematically searched for studies on the effects and in vivo changes caused by ADSC intervention. Quality assessment was conducted using a 10-item risk of bias tool. For the subsequent meta-analysis, study characteristics were extracted and effect sizes were computed. Ten out of 2324 published articles (n = 169 animals) were selected for further meta-analysis. After ADSC therapy, the rotation behavior (10 experiments, n = 156 animals) and rotarod performance (3 experiments, n = 54 animals) were improved (P < 0.000 01 and P = 0.000 3, respectively). The rotation behavior test reflected functional recovery, which may be due to the neurogenesis from neuronally differentiated ADSCs, resulting in a higher pooled effect size of standard mean difference (SMD) (− 2.59; 95% CI, − 3.57 to − 1.61) when compared to that of primitive cells (− 2.18; 95% CI, − 3.29 to − 1.07). Stratified analyses by different time intervals indicated that ADSC intervention exhibited a long-term effect. Following the transplantation of ADSCs, tyrosine hydroxylase-positive neurons recovered in the lesion area with pooled SMD of 13.36 [6.85, 19.86]. Transplantation of ADSCs is a therapeutic option that shows long-lasting effects in animal models of PD. The potential mechanisms of ADSCs involve neurogenesis and neuroprotective effects. The standardized induction of neural form of transplanted ADSCs can lead to a future application in clinical practice.

Assessing neuroprotection in Parkinson’s disease: from the animal models to molecular neuroimaging in vivo

2006 ◽  
pp. 133-141 ◽  
Author(s):  
R. Ceravolo ◽  
P. Sgadò ◽  
D. Frosini ◽  
G. U. Corsini
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Animal Models

Continuous Dopaminergic Stimulation in Parkinson's Disease - What Have We Learned from Positron-emission Tomography?

2010 ◽  
Vol 5 (1) ◽  
pp. 22
Author(s):  
David J Brooks ◽  
Nicola Pavese ◽  
◽  
Keyword(s):  
Parkinson’S Disease ◽  
Positron Emission Tomography ◽  
Parkinson's Disease ◽  
Monoamine Oxidase Inhibitor ◽  
Oxidase Inhibitor ◽  
Emission Tomography ◽  
Continuous Dopaminergic Stimulation ◽  
Positron Emission ◽  
Significant Step ◽  
Dopaminergic Stimulation

The hypothesis that pulsatile stimulation of striatal dopamine receptors in Parkinson's disease (PD) induces molecular and physiological changes in basal ganglia neurons and may contribute to the development of motor complications has led to the design of therapeutic strategies that provide more continuous dopaminergic stimulation. Newer agents and drug-delivery systems, such as slow-release preparations, catechol- O-methyltransferase and monoamine oxidase inhibitor agents, apomorphine and Duodopa™infusions, represent a significant step towards less pulsatile dopaminergic administration. However, their efficacy in providing steady brain levels of dopaminergic stimulation in the short and longer term has not yet been proved in patients. This article briefly reviews and discusses the findings of published positron-emission tomography (PET) studies that support or oppose the value of continuous dopaminergic stimulation in PD. The potential future value of PET for proof of mechanism in this area is also debated.

scholarly journals Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities

2020 ◽  
Vol 35 (10) ◽  
pp. 1731-1744 ◽  
Author(s):  
C. Warren Olanow ◽  
Paolo Calabresi ◽  
Jose A. Obeso
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Current Status ◽  
Continuous Dopaminergic Stimulation ◽  
Dopaminergic Stimulation

Non-motor Symptoms in Late-stage Parkinson’s Disease – Is Continuous Dopaminergic Stimulation Beneficial?

2008 ◽  
Vol 3 (2) ◽  
pp. 45
Author(s):  
Prashanth Reddy ◽  
Vinod Metta ◽  
K Ray Chaudhuri ◽  
◽  
◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Late Stage ◽  
Motor Symptoms ◽  
Continuous Dopaminergic Stimulation ◽  
Non Motor Symptoms ◽  
Dopaminergic Stimulation

Sign in / Sign up

Export Citation Format

Share Document